RxDoctor Payments Data

Jill Vincent

Radiation Oncology · New Orleans, LANPI 1730488974

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.2% of the total across 34 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Novocure Inc. at 31.9% of the total. Reporting peaked in 2019 at $357 and has fallen 50.3% since, to $178 in 2025.

$709in general payments, 2019–2025

Across 34 payments — averaging $20.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novocure Inc.$226
  • Merck$96
  • Eisai Inc.$53
  • Agios Pharmaceuticals, Inc.$41
  • AstraZeneca$35
  • Bristol Myers Squibb$34
  • plus $224 from 14 others

What the payments were for

  • Food & beverage$69698%
  • Education$132%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$709 in reported general payments places this provider in the 60th percentile of 58 radiation oncology providers in Louisiana.

See all radiation oncology providers in Louisiana

Medicare billing

Part B allowed, 2024
$84,372
Medicare patients
111
Services billed
965

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen52$2,314
Gabapentin28$676
Lidocaine Hcl ViscousLidocaine Hcl28$570
Tamsulosin Hcl29$316
SsdSilver Sulfadiazine13$178
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen12$148
Tramadol Hcl11$43

Paid to pharmacies, not to this prescriber.

Other radiation oncology in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →